Special Issue "The Evolving Landscape of Systemic Therapies and Oncology Outcomes"
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 31 December 2022 | Viewed by 378
Interests: Chemotherapy; Medical Oncology; Renal Cell Carcinoma; Prostate Cancer; Transitional Cell Carcinoma; Germ Cell Tumors; Public Health; Grastric Cancer; Esophageal Cancer; Pancreatic Cancer
Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada
Interests: clinical trials; precision oncology; breast cancer and melanoma
Over the last decades, the armamentarium of systemic therapies against cancer has expanded to include immunotherapy and targeted therapies in addition to the traditional cytotoxic chemotherapies and endocrine therapies. These novel therapies have improved survival outcomes for selected patients and questioned whether surrogates of progression-free survival or response rates for overall survival are appropriate for patients treated with modalities.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:
- Immunotherapy past, present and future: how it changed patient's survival and raise the need for new oncology endpoints.
- The emergence of novel immunotherapies to overcome resistance and sensitize cold tumor to improve outcomes
- Next generation sequencing and personalized medicine: How it transformed new drugs development and clinical trial research
- Surrogate endpoints in the era of targeted therapy and immunotherapy
- Epidemiologic perspective on the emergence of novel systemic therapies including impact on clinical outcomes, social cost and impacts on disparities within developed and across developing countries..
We look forward to receiving your contributions.
Dr. Dominik Bosse
Dr. Arif Awan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- survival outcomes
- next-generation sequencing
- clinical trials
- new drug development